UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000045448
Receipt number R000051879
Scientific Title A multicenter external validation of individualized infusion rates of intravenous lipid emulsion
Date of disclosure of the study information 2021/09/10
Last modified on 2023/03/06 17:26:11

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

A multicenter external validation of individualized infusion rates of intravenous lipid emulsion

Acronym

External validation of individualized infusion rates of intravenous lipid emulsion

Scientific Title

A multicenter external validation of individualized infusion rates of intravenous lipid emulsion

Scientific Title:Acronym

External validation of individualized infusion rates of intravenous lipid emulsion

Region

Japan


Condition

Condition

Inpatients who initially receives intravenous lipid emulsion

Classification by specialty

Not applicable

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To validate the individualized infusion rates of intravenous lipid emulsion with external data, based on the developed population triglyceride kinetic model

Basic objectives2

Others

Basic objectives -Others

To assess the efficacy and safety of the individualized infusion rates

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Infusion times required and the maximum triglyceride concentrations during the infusion

Key secondary outcomes



Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification

NO

Dynamic allocation

YES

Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Using triglyceride concentration just before the infusion and body weight, the maximum acceptable infusion rate for each patient is calculated from the developed population triglyceride kinetic model and infused.
* Interventions are performed only at the infusion rate at the initial use, not at the dosage of fat.

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

18 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Patients who are judged to need intravenous lipid emulsion and obtained written informed consent

Key exclusion criteria

Patients younger than 18 years, those with baseline triglyceride concentrations exceeding 300 mg/dL, and those with incomplete data

Target sample size

100


Research contact person

Name of lead principal investigator

1st name Keizo
Middle name
Last name Fukushima

Organization

Kobe Gakuin University

Division name

Faculty of Pharmaceutical Sciences

Zip code

650-8586

Address

1-1-3 Minatojima, Chuo district, Kobe city, Hyogo prefecture, Japan

TEL

078-974-4441

Email

keizo@pharm.kobegakuin.ac.jp


Public contact

Name of contact person

1st name Keizo
Middle name
Last name Fukushima

Organization

Kobe Gakuin University

Division name

Faculty of Pharmaceutical Sciences

Zip code

650-8586

Address

1-1-3 Minatojima, Chuo district, Kobe city, Hyogo prefecture, Japan

TEL

078-974-4441

Homepage URL


Email

keizo@pharm.kobegakuin.ac.jp


Sponsor or person

Institute

Kobe Gakuin University

Institute

Department

Personal name



Funding Source

Organization

Kobe Gakuin University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor

Ageo Central General Hospital
Joetsu GeneralHospital

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Ageo Central General Hospital

Address

1-10-10 Kashiwaza, Ageo city, Saitama prefecture, Japan

Tel

048-773-1111

Email

N/A


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

上尾中央総合病院(埼玉)、上越総合病院(新潟)


Other administrative information

Date of disclosure of the study information

2021 Year 09 Month 10 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2021 Year 07 Month 05 Day

Date of IRB

2021 Year 07 Month 30 Day

Anticipated trial start date

2021 Year 10 Month 01 Day

Last follow-up date

2022 Year 10 Month 31 Day

Date of closure to data entry

2022 Year 10 Month 31 Day

Date trial data considered complete

2022 Year 10 Month 31 Day

Date analysis concluded

2023 Year 10 Month 31 Day


Other

Other related information

Enrollment of all targeted cases (n=100) was completed by the end of the follow-up data (2022.10.31).


Management information

Registered date

2021 Year 09 Month 10 Day

Last modified on

2023 Year 03 Month 06 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000051879


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name